Literature DB >> 21425122

Protein kinase Cδ and c-Abl kinase are required for transforming growth factor β induction of endothelial-mesenchymal transition in vitro.

Zhaodong Li1, Sergio A Jimenez.   

Abstract

OBJECTIVE: The origin of the mesenchymal cells responsible for the intimal fibrosis in systemic sclerosis (SSc) has not been fully identified. The present study was undertaken to investigate whether subendothelial mesenchymal cells may emerge through transdifferentiation of endothelial cells (ECs) into myofibroblasts via endothelial-mesenchymal transition (EndoMT) in vitro and to explore the signaling pathways involved in this process.
METHODS: Primary mouse pulmonary ECs isolated by immunomagnetic methods with sequential anti-CD34 and anti-CD102 antibody selection were cultured in monolayers. Cell morphology and diacetylated low-density lipoprotein uptake assays confirmed their EC characteristics. The induction of EndoMT was assessed by determination of α-smooth muscle actin (α-SMA), type I collagen, and VE-cadherin expression, and the expression of the transcriptional repressor Snail-1 was analyzed. The signaling pathways involved were examined using small-molecule kinase inhibitors and RNA interference.
RESULTS: Transforming growth factor β1 (TGFβ1) induced α-SMA and type I collagen expression and inhibited VE-cadherin. These effects were mediated by a marked increase in Snail-1 expression and were abolished by treatment with either the c-Abl tyrosine kinase inhibitor imatinib mesylate or the protein kinase Cδ (PKCδ) inhibitor rottlerin. The inhibitory effects of imatinib mesylate and rottlerin were mediated by inhibition of phosphorylation of glycogen synthase kinase 3β at residue Ser(9). These observations were confirmed in experiments using small interfering RNA specific for c-Abl and PKCδ.
CONCLUSION: These results indicate that c-Abl and PKCδ are crucial for TGFβ-induced EndoMT and that imatinib mesylate and rottlerin or similar kinase inhibitor molecules may be effective therapeutic agents for SSc and other fibroproliferative vasculopathies in which EndoMT plays a pathogenetic role.
Copyright © 2011 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21425122      PMCID: PMC3134600          DOI: 10.1002/art.30317

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  41 in total

1.  The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression.

Authors:  A Cano; M A Pérez-Moreno; I Rodrigo; A Locascio; M J Blanco; M G del Barrio; F Portillo; M A Nieto
Journal:  Nat Cell Biol       Date:  2000-02       Impact factor: 28.824

2.  The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells.

Authors:  E Batlle; E Sancho; C Francí; D Domínguez; M Monfar; J Baulida; A García De Herreros
Journal:  Nat Cell Biol       Date:  2000-02       Impact factor: 28.824

Review 3.  TGF-beta and fibrosis.

Authors:  M H Branton; J B Kopp
Journal:  Microbes Infect       Date:  1999-12       Impact factor: 2.700

Review 4.  Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.

Authors:  J H W Distler; O Distler
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

5.  A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition.

Authors:  Theresa Vincent; Etienne P A Neve; Jill R Johnson; Alexander Kukalev; Federico Rojo; Joan Albanell; Kristian Pietras; Ismo Virtanen; Lennart Philipson; Philip L Leopold; Ronald G Crystal; Antonio Garcia de Herreros; Aristidis Moustakas; Ralf F Pettersson; Jonas Fuxe
Journal:  Nat Cell Biol       Date:  2009-07-13       Impact factor: 28.824

Review 6.  Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies.

Authors:  Joel Rosenbloom; Susan V Castro; Sergio A Jimenez
Journal:  Ann Intern Med       Date:  2010-02-02       Impact factor: 25.391

7.  Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis.

Authors:  Naozumi Hashimoto; Sem H Phan; Kazuyoshi Imaizumi; Masaki Matsuo; Harunori Nakashima; Tsutomu Kawabe; Kaoru Shimokata; Yoshinori Hasegawa
Journal:  Am J Respir Cell Mol Biol       Date:  2009-09-18       Impact factor: 6.914

8.  Epithelial-Mesenchymal Transitions in development and disease: old views and new perspectives.

Authors:  M Angela Nieto
Journal:  Int J Dev Biol       Date:  2009       Impact factor: 2.203

9.  Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice.

Authors:  Jinhua Li; Xinli Qu; John F Bertram
Journal:  Am J Pathol       Date:  2009-09-03       Impact factor: 4.307

Review 10.  Transforming growth factor-beta in systemic sclerosis (scleroderma).

Authors:  John Varga; Michael L Whitfield
Journal:  Front Biosci (Schol Ed)       Date:  2009-06-01
View more
  47 in total

Review 1.  Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.

Authors:  Swati Bhattacharyya; Jun Wei; John Varga
Journal:  Nat Rev Rheumatol       Date:  2011-10-25       Impact factor: 20.543

Review 2.  Recent developments in myofibroblast biology: paradigms for connective tissue remodeling.

Authors:  Boris Hinz; Sem H Phan; Victor J Thannickal; Marco Prunotto; Alexis Desmoulière; John Varga; Olivier De Wever; Marc Mareel; Giulio Gabbiani
Journal:  Am J Pathol       Date:  2012-03-02       Impact factor: 4.307

Review 3.  Vasculopathy in scleroderma.

Authors:  Yoshihide Asano; Shinichi Sato
Journal:  Semin Immunopathol       Date:  2015-07-08       Impact factor: 9.623

Review 4.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

5.  Disease modification in systemic sclerosis. Do integrated approaches offer new challenges?

Authors:  M Cutolo
Journal:  Z Rheumatol       Date:  2013-05       Impact factor: 1.372

6.  Transcription factor TBX4 regulates myofibroblast accumulation and lung fibrosis.

Authors:  Ting Xie; Jiurong Liang; Ningshan Liu; Caijuan Huan; Yanli Zhang; Weijia Liu; Maya Kumar; Rui Xiao; Jeanine D'Armiento; Daniel Metzger; Pierre Chambon; Virginia E Papaioannou; Barry R Stripp; Dianhua Jiang; Paul W Noble
Journal:  J Clin Invest       Date:  2016-07-11       Impact factor: 14.808

Review 7.  The Primary Cilium: Emerging Role as a Key Player in Fibrosis.

Authors:  Maria E Teves; Jerome F Strauss; Paulene Sapao; Bo Shi; John Varga
Journal:  Curr Rheumatol Rep       Date:  2019-05-21       Impact factor: 4.592

8.  The Activation of Human Dermal Microvascular Cells by Poly(I:C), Lipopolysaccharide, Imiquimod, and ODN2395 Is Mediated by the Fli1/FOXO3A Pathway.

Authors:  Lukasz Stawski; Grace Marden; Maria Trojanowska
Journal:  J Immunol       Date:  2017-11-15       Impact factor: 5.422

Review 9.  Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders.

Authors:  Sonsoles Piera-Velazquez; Zhaodong Li; Sergio A Jimenez
Journal:  Am J Pathol       Date:  2011-07-19       Impact factor: 4.307

10.  Interferon-γ promotes vascular remodeling in human microvascular endothelial cells by upregulating endothelin (ET)-1 and transforming growth factor (TGF) β2.

Authors:  Izabela Chrobak; Stefania Lenna; Lukasz Stawski; Maria Trojanowska
Journal:  J Cell Physiol       Date:  2013-08       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.